Electric motor and controller manufacturer YASA closes £18m funding round, sets stage for rapid growth
10.9.2019 08:05:00 EEST | Business Wire | Press release
YASA, the world’s leading manufacturer of axial-flux electric motors and controllers for hybrid and pure electric vehicles, today announced closing a £18m (€20m) funding round. The new funding will enable the company to scale to meet rapidly growing customer demand from the automotive and aerospace sectors. Existing investors Parkwalk Advisors and Universal Partners have been joined in the round by Oxford Sciences Innovation (OSI) and Inovia Capital.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190909005993/en/
YASA P400 axial-flux electric motor (Photo: Business Wire)
YASA’s innovative axial-flux electric motor and controller designs offer best-in-class power and torque densities and are ideally suited to both hybrid and pure electric applications, allowing manufacturers to improve electric vehicle performance whilst reducing vehicle weight.
This news follows YASA’s announcement in May 2019 that a luxury hybrid electric car now in series production is powered by a custom YASA motor.
Speaking of the new funding round, Charles Conn CEO at OSI said, “We have been tracking YASA’s progress for a number of years and are pleased to have the opportunity to invest in one of the UK’s most exciting high-growth technology companies that is well positioned to take advantage of the rapid move to electrification in both automotive and aerospace sectors.”
Patrick Pichette, General Partner at Inovia Capital said, “YASA exemplifies what we look for in our portfolio companies – a company with high-growth potential and a team that’s passionate about building a better world through the discovery and application of innovative technology. YASA’s electric motors and controllers are opening up entirely new opportunities for vehicle manufacturers, enabling them to create exciting electric driving experiences while reducing the impact on the environment. We look forward to enabling the company to grow and secure its place at the centre of the electrification revolution.”
Dr. Chris Harris, YASA’s CEO said, “This funding round is helping prepare the company to meet the rapidly increasing volume of demand for our electric motors and controllers from our automotive customers. We’re pleased to welcome OSI and Inovia onboard as investors – both share our long-term vision for the company and bring tremendous operational experience that will help us realise our full potential.”
<ends>
EDITOR’S NOTES
YASA is the world’s leading manufacturer of axial-flux electric motors and controllers for automotive and aerospace applications. YASA’s proprietary electric motor and controller products offer the smallest, lightest form factor for a given power and torque requirement. The privately-held company is based in Oxford, the UK’s automotive manufacturing heartland. Investors include Parkwalk Advisors, Universal Partners, Oxford Sciences Innovation (OSI) and Inovia Capital.
Inovia Capital https://inovia.vc
Inovia Capital is a full-stack venture firm that partners with audacious founders to build enduring global technology companies. We seek to transform venture capital by perfecting the craft of investing in people first. We roll up our sleeves to serve founders with dedicated, long-term mentorship, a global talent network, and strategic support for global scale. Together, we rewrite the rules of complex legacy industries, push technology frontiers and pursue bold visions of a better future. Inovia Capital manages over US $1B across five funds including early and growth stages, and holds offices in Montreal, Toronto, Calgary, San Francisco and London.
Oxford Sciences Innovation https://www.oxfordsciencesinnovation.com
OSI is the venture firm formed in partnership with Oxford University to develop its advanced science into new platform companies. OSI has raised £600m from GV, Lansdowne, Sequoia, Temasek, Tencent, Wellcome and other global investors, and has been helping scientists build businesses that address global challenges - from infectious diseases to renewable energy - since 2015.
Parkwalk http://parkwalkadvisors.com
Parkwalk is the largest growth EIS fund manager, backing world-changing technologies emerging from the UK’s leading universities and research institutions. With £250m of assets under management, it has invested in over 100 companies across its flagship Parkwalk Opportunities EIS Fund as well as the award-winning enterprise and innovation funds Parkwalk manages for the Universities of Cambridge, Oxford and Bristol.
Parkwalk invests in businesses creating solutions to real-world challenges, with IP-protected innovations, across a range of sectors including life sciences, AI, quantum computing, advanced materials, genomics, cleantech, future of mobility, MedTech and big data.
Universal Partners http://www.universalpartners.mu
Universal Partners Limited (“Universal Partners”), an investment holding company domiciled in Mauritius and listed on the Stock Exchange of Mauritius and JSE Securities Exchange, is an investor in owner managed, founder led, high potential companies that require growth capital and strategic assistance to achieve their potential. Universal Partners has an experienced Board of Directors and Management team, who have grown a variety of businesses in different industries and geographic regions, in private and public markets. Universal Partners has to date invested in a portfolio of fast growing companies, where it has been able to partner with management and other shareholders to facilitate achievement of ambitious business plans.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005993/en/
Contact information
Tamara Sword
media@yasa.com
+44 (0)7906 638351
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom